We are live on ! Find out more
DCOY

Decoy Therapeutics
DCOY

7 hedge funds and large institutions have $102K invested in Decoy Therapeutics in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

30% less funds holding

Funds holding: 10 → 7 (-3)

40% less capital invested

Capital invested by funds: $170K → $102K (-$67.9K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
7
Holders Change
-3
Holders Change %
-30%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$1.72K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$19.5K
2
Citadel Advisors
Citadel Advisors
Florida
-$15.7K
3
TSS
Two Sigma Securities
New York
-$8.45K
4
AC
Armistice Capital
New York
-$2.58K

DCOY Hedge Fund Activity: Q1 2024 in Review

7 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q1 2024, worth a combined $102K — down 40% from $170K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of DCOY and 0 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Renaissance Technologies, adding an estimated $1.72K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $19.5K sold.

  • 7 institutional investors held Decoy Therapeutics (DCOY) as of Q1 2024, down from 10 in Q4 2023.
  • Funds reported $102K of Decoy Therapeutics stock for Q1 2024, down 40% quarter-over-quarter.
  • 0 funds opened new Decoy Therapeutics positions in Q1 2024 and 3 closed out, a net change of -3 holders.
  • The largest Decoy Therapeutics buyer in Q1 2024 was Renaissance Technologies, an estimated $1.72K added.
  • The largest Decoy Therapeutics seller in Q1 2024 was Susquehanna International Group, an estimated $19.5K sold.

Based on aggregated 13F filings for Q1 2024.